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Abstract 
The present study is an exploratory analysis of the “Metformin for Weight Loss and Metabolic 
Control in Overweight Patients with Schizophrenia and Schizoaffective Disorder” (METS) 
report. This exploratory analysis categorizes participants of METS into groups based on their 
individual antipsychotics, allowing for a comparative analysis of metabolic responses to 
metformin between individual antipsychotic groups. Our methods employ the Linear Mixed 
Effects Model to determine time-by-treatment effects of individual antipsychotics on key 
metabolic variables: total cholesterol (mg/dL), fasting glucose (mg/dL), triglycerides (mg/dL), 
and weight (kg). Results show a highly significant time-by-treatment effect (p=0.0009) of 
metformin on weight loss for patients taking clozapine, with a large metformin-placebo group 
difference in weight loss of -7.3 kg. The results suggest that metabolic responses to metformin 
might vary widely depending on a patient’s individual antipsychotic. Furthermore, this analysis 
suggests that the standard analytic procedure of grouping antipsychotics into higher-risk for 
weight gain or lower-risk for weight gain is insufficient for detecting potentially nuanced 
metabolic responses associated with individual antipsychotics and adjuvant metformin. Future 
studies should investigate metformin-associated weight loss in individuals taking clozapine, 
which the present study found to be highly significant. In addition, larger studies and meta-
analyses are needed to determine a significant time-by-treatment effect of metformin on the 
metabolic variables: total cholesterol, fasting glucose, and triglycerides. 
Keywords: Metformin, Weight Loss, Schizophrenia, Antipsychotics, Clozapine, Aripiprazole, 
Olanzapine, Risperidone, Quetiapine, Cholesterol, Triglycerides, Glucose.  
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An Antipsychotic-Specific Analysis of Metformin for Weight Loss and  
Metabolic Control in Overweight Patients with Schizophrenia and Schizoaffective Disorder 
Despite the effectiveness of antipsychotics for attenuating psychotic symptoms, 
antipsychotic-associated weight is a significant clinical complication in the treatment of patients 
with Schizophrenia or Schizoaffective Disorder. The Metformin for Weight Loss Study (METS) 
showed that metformin, a biguanide antihyperglycemic drug approved for the treatment of 
diabetes mellitus, has moderate efficacy for attenuating antipsychotic-associated weight gain 
and concluded that metformin is a reasonable option for weight management in patients whose 
current antipsychotic, such as clozapine, proves clinically efficacious though incurs significant 
risk for weight gain (Jarskog et al., 2013). Past research has investigated the differential health 
risks of individual antipsychotics, however no research has investigated the differential efficacy 
of metformin for attenuating these health risks (Leucht et al., 2013). While METS primarily 
compared changes in average weight between metformin and placebo groups, the present sub-
analysis of METS investigates changes in weight (kg), total cholesterol (mg/dL), fasting glucose 
(mg/dL), and triglycerides levels (mg/dL) for METS participants within categories of individual 
antipsychotics, including aripiprazole, clozapine, olanzapine, risperidone, and quetiapine. The 
objective of this exploratory analysis of METS is to provide a more nuanced, antipsychotic-
specific description of metformin’s efficacy for the management of weight, total cholesterol, 
fasting glucose, and triglycerides in patients with Schizophrenia or Schizoaffective Disorder. 
Antipsychotic-Associated Metabolic Risks 
Weight. Antipsychotic-associated weight gain poses significant cardiovascular-related 
health problems such as cardiovascular disease for patients with schizophrenia who are 
receiving antipsychotics (Bak, Fransen, Janssen, van Os, & Drukker, 2014; Correll et al., 2009; 
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Manu et al., 2015; Olfson, Gerhard, Huang, Crystal, & Stroup, 2015; Osby, Correia, Brandt, 
Ekbom, & Sparén, 2000). Despite antipsychotics’ risks for cardiovascular disease, research 
supports the clinical efficacy of antipsychotics, especially for the high-weight-liability 
antipsychotic clozapine, in the treatment of schizophrenia (Meltzer, 2012; Tiihonen et al., 
2006). Furthermore, treatment with antipsychotics still generally reduces mortality as opposed 
to treatment without antipsychotics (Tiihonen et al., 2009).  
Risk for weight gain and cardiovascular disease vary by the type of antipsychotic a 
patient takes (Tek et al., 2015). Research shows clozapine and olanzapine to have high liability 
for weight gain, quetiapine and risperidone to have intermediate-liability for weight gain, and 
aripiprazole to have low-liability for weight gain (Correll, Lencz, & Malhotra, 2010; Daumit et 
al., 2009; Rummel-Kluge et al., 2010). Despite its high liability for weight gain, clozapine is an 
especially effective antipsychotic for treatment-resistant schizophrenia (Kane & Correll, 2015). 
In addition, a study showed that participants who received the greatest clinical benefit from the 
antipsychotics clozapine and olanzapine were also those who had the highest risk for weight 
gain (Czobor et al., 2002). Among efforts to find a strategy for mitigating antipsychotic-
associated weight gain, one study showed that switching a patient’s antipsychotic from 
olanzapine, quetiapine, or risperidone to the low weight-liability antipsychotic aripiprazole 
proved effective (Stroup et al., 2011). However, switching antipsychotics purely to avoid weight 
loss is inadvisable, especially in cases where risk to clinical stability is high (Jarskog et al., 
2013). Because weight gain is often an unavoidable consequence of treatment with highly 
efficacious antipsychotics such as clozapine, novel interventions are needed for attenuating 
increases in weight.  
Total Cholesterol, Fasting Glucose, and Triglycerides. In conjunction with weight 
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gain, increases in total cholesterol, fasting glucose, and triglyceride levels raise risks for 
cardiovascular illness. Studies show that clozapine and olanzapine are associated with increases 
in total cholesterol, fasting glucose and triglyceride levels, whereas risperidone and quetiapine 
are associated with moderate to small changes in fasting glucose and triglyceride levels and 
have no clear association with total cholesterol (Atmaca, Kuloglu, Tezcan, & Ustundag, 2003; 
Lindenmayer et al., 2003; Wirshing et al., 2002). High risk for weight gain of clozapine and 
olanzapine is likely associated with the increases in fasting glucose and triglyceride levels 
observed in prior studies. Additionally, the low risk for weight gain of risperidone and 
quetiapine might also be associated with the negligible effect on fasting glucose and triglyceride 
levels. 
Intervention with Metformin 
Metformin for Attenuating Antipsychotic-Associated Weight Gain. In addition to 
treating symptoms of psychosis, clinicians have shown interest in ameliorating weight gain 
associated with antipsychotics (Correll, Detraux, De Lepeleire, & De Hert, 2015; Pringsheim et 
al., 2017). Efforts to find an interventional drug that reduces antipsychotic-associated weight 
gain have yielded favorable results, and metformin seems to be the most efficacious at reducing 
antipsychotic-associated weight gain (Björkhem-Bergman, Asplund, & Lindh, 2011; 
Fiedorowicz et al., 2012; Mizuno et al., 2014; Wang et al., 2013; Wu et al., 2008). One study 
added the stipulation that the efficacy of metformin for weight loss increases after an initial 
period of antipsychotic-associated weight gain, suggesting that Metformin is appropriate for 
patients who have already gained weight as opposed to patients who are beginning treatment 
(Maayan, Vakhrusheva, & Correll, 2010).  
 Collective Results from METS. In the original METS analysis, the weight change 
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during the 16-week treatment duration was -3.0 kg in the metformin group and -1.0 kg in the 
placebo group, with a between-group difference of -2.0 kg and a significant time-by-treatment 
interaction (p=0.007). The change in triglyceride levels was -7.0 mg/dL in the metformin group 
and 13.2 mg/dL in the placebo group, with a between-group difference of -20.2 mg/dL and a 
significant time-by-treatment interaction (p=0.04). There was no difference in fasting glucose 
levels between metformin and placebo groups, and the differences in total cholesterol between 
metformin and placebo groups were statistically insignificant.  
Current Study. While Metformin demonstrates efficacy for attenuating antipsychotic-
associated weight gain, there is no consensus on which antipsychotics respond most favorably 
to intervention with metformin in terms of weight and other metabolic variables. The current 
study compares the METS between-antipsychotic group changes in weight, total cholesterol, 
fasting glucose, and triglyceride levels. To our knowledge, no metformin intervention for 
weight loss study has conducted a secondary analysis examining the relationship between 
individual antipsychotics and weight loss. The present analysis is intended to aid physicians 
who would like to prescribe metformin to reduce antipsychotic-associated weight gain, but who 
are unsure about which antipsychotics will respond most favorably.  
Methods 
Overview 
The present study is an exploratory analysis of METS, which investigated the efficacy of 
metformin as an interventional agent for managing antipsychotic-induced weight gain. While 
METS found averaged across-antipsychotic groups changes in weight and other metabolic 
variables, this sub-analysis compares individual antipsychotics with weight (kg), total 
cholesterol (mg/dL), fasting glucose (mg/dL), and triglycerides (mg/dL).  
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Participants 
The METS sample included 146 participants (age M=43.20, SD=11.06). There were a 
total number of 12 individual antipsychotics represented in the study population, with 
aripiprazole (N=36; MET=19, PLB=17), clozapine (N=32; MET=17, PLB=15), risperidone 
(N=31; MET=13, PLB=18), olanzapine (N=28; MET=14, PLB=14), and quetiapine (N=15; 
MET=10, PLB=5) being the most common.  
Procedure 
Mean Change and Percent Change. The primary variables of interest are participants’ 
individual antipsychotics and their recorded changes in weight (kg), total cholesterol (mg/dL), 
fasting glucose (mg/dL), and triglycerides (mg/dL). The analysis will divide METS participants 
into groups based on their individual antipsychotics, allocating participants taking two or more 
antipsychotics into each corresponding individual antipsychotic group. The 5 antipsychotics 
investigated in this primary analysis are aripiprazole (N=36), clozapine (N=32), risperidone 
(N=31), olanzapine (N=28), and quetiapine (N=15). Each antipsychotic group is divided into 
participants receiving metformin or placebo. For participants in each of the 5 antipsychotic 
groups, measures of the metabolic variables of interest at baseline and at the 16-week 
conclusion of METS are required for our calculations. For all 5 antipsychotic groups, 
calculations will be done for the average change and the average percent change for each 
metabolic variable. A percent change in weight greater than 5.0% is clinically significant. 
The Linear Mixed Effects Model. We used the linear mixed effects model, which is 
appropriate for analyzing inherently unbalanced longitudinal data sets. The linear mixed effects 
model allows us to find fixed and random effects and interactions of multiple variables, 
including both time and treatment variables. In addition, the linear mixed effects model 
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mitigates subject-shared and subject-specific sources of variation in the longitudinal response 
to treatment via averaging methods. In this study, we focus on using the linear mixed effects 
model to estimate parameters that describe the mean response changes in the population of 
interest, and we exclude predictions about individual response trajectories. 
We used the following model for population-averaged changes in each metabolic 
variable (𝑌!). E 𝑌! = 𝛽! + 𝛽!𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡! + 𝛽!𝑡𝑖𝑚𝑒!" + 𝛽!𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡!×𝑡𝑖𝑚𝑒!" 
The regression parameters β represent fixed effects, which describe patterns of change in 
the mean response over time in the population of interest for each metabolic variable. For each 
metabolic variable, the parameters β are assumed to be the same for all individuals and have 
population-averaged interpretations. The variable 𝑌!   denotes the value of the metabolic response 
of interest of the 𝑖!! subject. 𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡!= 1 if the 𝑖!!  subject is randomized to metformin 
group, and 𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡!= 0 otherwise. The variable 𝑡𝑖𝑚𝑒!"   denotes the time since baseline for 
the 𝑗!!measurement on the 𝑖!! subject (with 𝑡!"= 0 at baseline and 𝑡!"= 16 at week 16). For each 
respective metabolic variable, 𝛽! is the averaged baseline measure and remains fixed for both 
metformin and placebo groups. The variable 𝛽! is the averaged effect of treatment (metformin), 
and 𝛽!𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡! simply equals a value of 𝛽! for metformin and 0 for placebo. The variable 𝛽! represents the fixed time effect for each respective metabolic variable. The value of the term 𝛽!𝑡𝑖𝑚𝑒!"   is identical for both metformin and placebo groups, as both metformin and placebo 
remain in the study for 16 weeks; the summation of 𝛽!𝑡𝑖𝑚𝑒!" and 𝛽! equals the averaged 
baseline weight in the metformin group, whereas the term 𝛽! alone equals the baseline weight in 
the placebo group. The value 𝛽! is a measure of the fixed treatment-by-time effect for 
metformin. The term 𝛽!𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡!×𝑡𝑖𝑚𝑒!" equals a value of 0 in the placebo group, as there 
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is no treatment, and 𝛽!×1×16 in the metformin group. The linear mixed effects model 
ultimately generates an equation that is capable of calculating respective metabolic responses to 
metformin for each individual antipsychotic. In its final form, the only difference in the 
equation between metformin and placebo is the treatment-by-time effect (𝛽!𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡!×𝑡𝑖𝑚𝑒!"), and thus the treatment-by-time effect is the most important measure for determining the 
clinical efficacy of metformin. Subsequent p-tests will determine the levels of statistical 
significance for the treatment-by-time effects for each metabolic variable for each antipsychotic. 
The primary focus of the analysis will be the treatment-by-time effect, as this term reveals the 
clinical efficacy of metformin for attenuating metabolic variables of patients on different 
antipsychotics.  
In addition, equations from the linear mixed effects model will allow for the calculation 
of baseline and final metabolic measures. Basic arithmetic will provide values for the changes 
in metabolic responses for both metformin and placebo groups for each antipsychotic. The 
values of metformin-placebo differences in metabolic responses in across individual 
antipsychotics will provide the basis for qualitative analysis and trend comparison.  
Results 
Weight 
For clozapine, the weight lost in the metformin group (N=17) and placebo group (N=15) 
was -8.4 kg (-8.0% weight change) and -1.1 kg (-1.1% weight change), respectively; the 
metformin-placebo difference for clozapine was -7.3 kg (-6.9% difference in percent weight 
change). The time-by-treatment effect for clozapine was highly significant (p=0.001), which is 
remarkable given the small sample size for clozapine. The -8.0% reduction in body weight in 
the metformin group for clozapine is also clinically significant. The time-by-visit effects for 
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aripiprazole (p=0.161), olanzapine (p=0.193), risperidone (p=0.780), and quetiapine 
(p=0.822) all fell short of significance. However, for each antipsychotic, the metformin group 
experienced a greater percent reduction in weight than the placebo group. The metformin-
placebo differences in percent weight change descends in the order of clozapine at -6.9%, 
aripiprazole at -3.1%, olanzapine at -2.9%, quetiapine at -0.9%, and risperidone at -0.8%. 
Total Cholesterol 
Aripiprazole (p=0.249), risperidone (p=0.749), and quetiapine (p=0.178) showed 
insignificant time-by-treatment interactions with total cholesterol, and information about time-
by-treatment effect interactions with total cholesterol was unavailable for clozapine and 
olanzapine due to missing data.  
Metformin groups for both aripiprazole and clozapine experienced large increases in the 
average total cholesterol of 39.2 mg/dL and 30.6 mg/dL, respectively. However, placebo groups 
of aripiprazole and clozapine both experienced reductions in total choleseterol of -11.7 mg/dL 
and -26.4 mg/dL, respectively. The metformin-placebo difference for aripiprazole and clozapine 
in percent cholesterol change was 28.6% and 31.7%, respectively. The metformin group of 
risperidone experienced a large average increase of 24.7 mg/dL and a percent increase in total 
cholesterol of 15.3%, but the placebo group experienced a small increase of 7.8 mg/dL and a 
percent increase in total cholesterol of 3.7%. Olanzapine was associated with minimal change in 
total cholesterol for both metformin and placebo groups. The placebo group of quetiapine 
experienced the largest reduction in total cholesterol for any antipsychotic sub-group, with a 
total cholesterol change of -89.3 mg/dL or -37.6%. However, the metformin group of quetiapine 
experienced a small decrease in total cholesterol of -2.3 mg/dL or -1.2%. 
Fasting Glucose 
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Aripiprazole (p=0.144), clozapine (p=0.960), and risperidone (p=0.220) showed 
insignificant time-by-treatment interactions with fasting glucose, and information about time-
by-treatment interaction with fasting glucose was unavailable for olanzapine and quetiapine due 
to missing data.  
For aripiprazole, clozapine, and olanzapine, the metformin group experienced a larger 
percent change in fasting glucose than the placebo group. The metformin-placebo differences 
for aripiprazole, clozapine, and olanzapine were -28.0%, -1.3%, and -8.5%, respectively. For 
risperidone, the metformin group experienced a small percent increase in fasting glucose of 
1.2%, and the placebo group experienced a large percent reduction in fasting glucose of -21.9%, 
with a metformin-placebo difference of -23.1%. Fasting glucose data was unavailable for 
individuals taking quetiapine. The results for fasting glucose levels are more nuanced than the 
original METS analysis, which showed no metformin-placebo differences in fasting glucose 
levels.  
Triglycerides 
Aripiprazole (p=0.544), risperidone (p=0.786), and quetiapine (p=0.399) showed 
insignificant time-by-treatment interactions with triglycerides, and time-by-treatment 
interactions with triglycerides were incalculable for clozapine and olanzapine due to missing 
data.  
For both aripirazole and risperidone, metformin and placebo groups experienced 
significant percent increases in triglycerides, but the metformin group experienced a lesser 
percent increase, with a metformin-placeebo difference for aripiprazole and risperidone of -
23.9% and -12.5%, respectively. For clozapine, the metformin group experienced a modest 
percent increase in triglycerides of 7.2%, but the placebo group experienced a percent decrease 
 
ANTIPSYCHOTIC-SPECIFIC ANALYSIS OF METS 
	  
12 
of -21.7%, with a metformin-placebo difference of 28.9%. For olanzapine, both the 
metformin and placebo groups experienced a percent reduction in triglycerides of -29.1% and -
68.4%, respectively, with a metformin-placebo difference of 39.3%. Quetiapine was the only 
antipsychotic to have a large reduction in triglycerides for metformin equal to -25.3% and a 
large increase in triglycerides for placebo equal to 47.0%, with a between-group difference of -
72.3%. 
  Discussion 
Original Antipsychotic-Averaged Analysis vs. Current Antipsychotic-Specific Analysis 
Weight. In the original METS analysis, the metformin group experienced an average 
weight loss equal to -2.0 kg more than the placebo group. This antipsychotic-specific analysis 
shows that the aripiprazole, clozapine, and olanzapine groups experienced average metformin-
placebo differences in weight loss equal to -3.2 kg, -7.3 kg, and -2.8 kg, respectively. For 
clozapine, the time-by-treatment effect of the metformin group was significant (p=0.001), and 
the large reduction in mean weight of the metformin group (-8.4 kg) also represented a 
clinically significant percent reduction in body weight (-8.0%).  
In exploratory analyses of the original METS report, antipsychotics were grouped into 
higher-risk for weight gain and lower-risk for weight gain classifications, and their metformin-
placebo differences were equal to -1.5 kg and -2.3 kg, respectively. While olanzapine and 
clozapine both qualify as higher-risk for weight gain antipsychotics, they also experienced 
greater weight loss than represented in the higher-risk for weight gain group of the original 
METS analysis, with metformin-placebo differences equal to -7.3 kg (-6.9%) and -2.8 kg (-
2.9%), respectively. Furthermore, while aripiprazole was categorized as a lower-risk for weight 
gain antipsychotic, the metformin-placebo difference for aripiprazole of 3.2 kg (5.5%) was 
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larger than the average metformin-placebo difference reported for lower-risk for weight gain 
antipsychotics in the original METS study of -2.3 kg. The original METS study categorized 
clozapine, olanzapine, quetiapine, and risperidone as higher-risk for weight gain antipsychotics 
and categorized aripiprazole as a lower-risk for weight gain antipsychotic. However, averaging 
the weight loss values across antipsychotic groups obscured the individual weight loss observed 
in aripiprazole, clozapine, and olanzapine, which was larger for each of these antipsychotic 
groups than the averaged METS report showed. 
 Total Cholesterol. The original METS analysis reported that the average total 
cholesterol changes in the metformin and placebo groups were -8.9 mg/dL and 0.2 mg/dL, 
respectively. When the data is grouped into individual antipsychotic categories, a different trend 
is observed for both metformin and placebo groups. While the original METS analysis reported 
a decrease of -8.9 mg/dL in total cholesterol associated with metformin, the individual 
antipsychotics aripiprazole, clozapine, and risperidone showed large increases in total 
cholesterol of 39.2 mg/dL (22.3%), 30.6 mg/dL (17.9%), and 24.7 mg/dL (15.3%), respectively. 
Additionally, while the antipsychotic-averaged METS analysis reported an increase of 0.2 
mg/dL in total cholesterol associated with placebo, the placebo groups of the individual 
antipsychotics aripiprazole and clozapine showed large decreases in total cholesterol of -11.7 
mg/dL (-6.3%) and -26.4 mg/dL (-12.8%), respectively. When considering total cholesterol, 
averaging participants’ data across individual antipsychotics potentially conceals certain 
individual antipsychotic-metformin interactions.  
Fasting Glucose. Another area of difference between the original METS analysis and 
this exploratory analysis is that the METS analysis found no difference in fasting glucose levels 
between metformin and placebo groups whereas this exploratory analysis showed aripiprazole, 
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olanzapine, and risperidone all had moderate to large metformin-placebo differences in 
fasting glucose levels, with values -25.2 mg/dL (-14.0%, p=0.144), -10.0 mg/dL (-8.5%), and 
25.0 mg/dL (20.7%, p=0.220), respectively. For clozapine and quetiapine, this exploratory 
analysis showed small metformin-placebo differences in fasting glucose levels, which is 
consistent with the original METS analysis. It is possible that the metformin-placebo 
differences for aripiprazole, olanzapine, and risperidone were lost via averaging data across the 
entire population and across individual antipsychotics. While the time-by-treatment effects of 
metformin on fasting glucose levels were insignificant for aripiprazole (p=0.144) and 
olanzapine (p=0.220), the current analysis shows that the two drugs were associated with larger 
reductions in fasting glucose levels in metformin groups than in placebo groups. The lack of 
statistical significance in this comparison between aripiprazole and olanzapine might be 
attributable to the small sample size and the limitations of sub-sampling. The clinical 
improvement in fasting glucose levels for individuals taking aripiprazole or olanzapine with 
adjuvant metformin might mitigate antipsychotic-associated health risks in overweight patients 
with schizophrenia or schizoaffective disorder. 
Triglycerides. The original METS analysis reported an average change in triglycerides 
of -7.0 mg/dL for the metformin group and 13.2 mg/dL for the placebo group. However, the 
current analysis shows that patients in several antipsychotic groups who received adjuvant 
metformin experienced large increases in triglyceride levels. The metformin groups of 
aripiprazole, clozapine, and risperidone experienced mean increases in triglycerides equal to 
50.4 mg/dL (41.1%), 11.1 mg/dL (7.2%), and 53.8 mg/dL (52.5%), respectively. Only the 
metformin groups of olanzapine and quetiapine experienced mean decreases in triglycerides 
equal to -54.1 mg/dL (-29.1%) and -37.6 mg/dL (-25.3%), respectively. In the original METS 
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analysis, averaging across individual antipsychotics groups led a calculated mean 
triglycerides reduction for metformin equal to -7.0 mg/dL, which neglects the triglyceride 
increases calculated for aripiprazole, clozapine, and risperidone. Future studies and meta-
analyses should investigate the possibility that metformin causes increases in triglycerides for 
patients who take aripiprazole, clozapine, and risperidone. 
Limitations 
 The small sample sizes involved in sub-sampling are the primary limitations of this 
exploratory analysis. It is possible that, as a result of sub-sampling, confounding variables that 
were averaged in the original METS analysis were retained in the present analysis and thereby 
skewed the metabolic responses for individual antipsychotics. For this reason, we limited the 
analysis of individual antipsychotics to only those that had more than 15 participants. Based on 
the present analysis, larger sample sizes with higher heterogeneity of antipsychotics are 
recommended in order to rigorously randomize all individual antipsychotic groups and to ensure 
that the individual antipsychotic groups are large enough to have sufficient statistical power. 
Implications and Recommendations 
This exploratory analysis underscores the importance of investigating the individual 
antipsychotic profiles of patients who are receiving treatment with metformin or other adjuvant 
medications. Averaging across individual antipsychotic groups obscures potentially significant 
trends in metabolic responses.  
Categorizing antipsychotics according to established definitions of high-risk and low-
risk for weight gain might be overly simplistic, and insufficient for showing the differential 
metabolic responses of individual antipsychotics to weight-loss intervention drugs like 
metformin. Ignoring differential metabolic responses between individual antipsychotic groups 
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limits the interpretations of data and also potentially neglects important exceptions to across-
antipsychotic group averages. The most striking example is clozapine, which in this exploratory 
analysis had a highly significant weight loss effect compared to other antipsychotics. In the 
original METS analysis, the statistically significant time-by-treatment effect for clozapine was 
overlooked due to averaging clozapine with other antipsychotics. 
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Table 1 
 Solution for Fixed Effects for Metabolic Variables: Aripiprazole 
Effect Variable Estimate St. Error DF t-Value Pr>|t| 
B.L. (𝛽!) 
 
Cholesterol 
Glucose 
Triglycerides 
Weight 
184.11 
87.84 
159.80 
92.09 
14.87 
4.32 
25.59 
3.41 
30 
30 
30 
33 
12.38 
20.36 
6.24 
26.99 
<0.001 
<0.001 
<0.001 
<0.001 
MET (𝛽!) Cholesterol 
Glucose 
Triglycerides 
Weight 
-8.64 
8.37 
-37.15 
8.41 
20.49 
5.96 
37.14 
4.63 
3 
3 
3 
242 
-0.42 
1.40 
-1.00 
1.82 
0.702 
0.255 
0.391 
0.071 
Time (𝛽!) Cholesterol 
Glucose 
Triglycerides 
Weight 
-0.73 
1.16 
6.49 
-0.07 
1.61 
0.58 
3.33 
0.10 
27 
27 
27 
33 
-0.45 
2.00 
1.95 
-0.68 
0.655 
0.056 
0.062 
0.504 
Time*MET 
(𝛽!) Cholesterol Glucose 
Triglycerides 
Weight 
3.18 
-1.57 
-3.34 
-0.20 
2.23 
0.80 
4.90 
0.14 
3 
3 
3 
242 
1.43 
-1.97 
-0.68 
-1.41 
0.249 
0.144 
0.544 
0.161 
Note: Weight is in kg. Fasting Glucose, Total cholesterol, and Triglycerides are in mg/dL. MET 
is an abbreviation for metformin. B.L. is an abbreviation for baseline. Time*MET is an 
abbreviation for time-by-metformin (time-by-treatment). 
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Table 2 
Solution for Fixed Effects for Metabolic Variables: Clozapine 
Effect Variable Estimate St. Error DF t-Value Pr>|t| 
B.L. (𝛽!) 
 
Cholesterol 
Glucose 
Triglycerides 
Weight 
206.45 
108.50 
229.05 
103.31 
14.33 
5.77 
28.34 
3.97 
29 
29 
29 
30 
14.41 
18.80 
8.08 
26.01 
<0.001 
<0.001 
<0.001 
<0.001 
MET (𝛽!) Cholesterol 
Glucose 
Triglycerides 
Weight 
-35.45 
-7.83 
-73.71 
1.67 
19.83 
8.07 
38.84 
5.45 
0 
3 
0 
235 
-1.79 
-0.97 
-1.90 
0.31 
. 
0.403 
. 
0.760 
Time (𝛽!) Cholesterol 
Glucose 
Triglycerides 
Weight 
-1.65 
-0.36 
-3.10 
-0.05 
1.17 
0.78 
3.46 
0.10 
25 
25 
25 
30 
-1.40 
-0.46 
-0.90 
-0.49 
0.172 
0.649 
0.379 
0.627 
Time*MET 
(𝛽!) Cholesterol Glucose 
Triglycerides 
Weight 
3.56 
-0.06 
3.80 
-0.48 
1.59 
1.07 
4.65 
0.14 
0 
3 
0 
235 
2.25 
-0.05 
0.82 
-3.37 
. 
0.960 
. 
0.001 
Note: Weight is in kg. Fasting Glucose, Total cholesterol, and Triglycerides are in mg/dL. MET 
is an abbreviation for metformin. B.L. is an abbreviation for baseline. Time*MET is an 
abbreviation for time-by-metformin (time-by-treatment). 
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Table 3 
Solution for Fixed Effects for Metabolic Variables: Olanzapine 
Effect Variable Estimate St. Error DF t-Value Pr>|t| 
B.L. (𝛽!) 
 
Cholesterol 
Glucose 
Triglycerides 
Weight 
196.12	  96.79	  207.59	  104.59 
17.88	  8.59	  41.55	  4.34 
24	  24	  24	  26 
10.97	  11.27	  5.00	  24.10 
<0.001	  <0.001	  <0.001	  <0.001 
MET (𝛽!) Cholesterol 
Glucose 
Triglycerides 
Weight 
-­‐14.48 8.66 -­‐21.64 -­‐3.92 
24.90 11.87 57.37 6.14 
0 0 0 212 
-­‐0.58 0.73 -­‐0.38 -­‐0.64 
. . . 0.524 
Time (𝛽!) Cholesterol 
Glucose 
Triglycerides 
Weight 
0.23 -­‐0.68 -­‐8.88 -­‐0.11 
1.72 1.17 4.49 0.10 
21 21 21 26 
0.13 -­‐0.58 -­‐1.98 -­‐1.10 
0.897 0.568 0.062 0.282 
Time*MET 
(𝛽!) Cholesterol Glucose 
Triglycerides 
Weight 
-­‐0.30 -­‐0.63 5.50 -­‐0.18 
2.38 1.62 6.15 0.14 
0 0 0 212 
-­‐0.12 -­‐0.39 0.89 -­‐1.31 
. . . 0.193 
Note: Weight is in kg. Fasting Glucose, Total cholesterol, and Triglycerides are in mg/dL. MET 
is an abbreviation for metformin. B.L. is an abbreviation for baseline. Time*MET is an 
abbreviation for time-by-metformin (time-by-treatment). 
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Table 4 
Solution for Fixed Effects for Metabolic Variables: Risperidone 
Effect Variable Estimate St. Error DF t-Value Pr>|t| 
B.L. (𝛽!) 
 
Cholesterol 
Glucose 
Triglycerides 
Weight 
211.90	  109.15	  126.95	  102.27 
18.88	  4.40	  19.54	  4.74 
27	  27	  27	  28 
11.22	  24.83	  6.50	  21.56 
<0.001	  <0.001	  <0.001	  <0.001 
MET (𝛽!) Cholesterol 
Glucose 
Triglycerides 
Weight 
-­‐50.73 -­‐17.25 -­‐24.42 -­‐0.21 
29.06 7.20 30.11 7.50 
1 3 1 225 
-­‐1.75 -­‐2.39 -­‐0.81 -­‐0.03 
0.331 0.096 0.566 0.977 
Time (𝛽!) Cholesterol 
Glucose 
Triglycerides 
Weight 
0.49 -­‐1.49 5.16 -­‐0.17 
1.63 0.60 3.25 0.11 
24 24 24 28 
0.30 -­‐2.47 1.59 -­‐1.59 
0.768 0.021 0.126 0.124 
Time*MET 
(𝛽!) Cholesterol Glucose 
Triglycerides 
Weight 
1.06 1.56 -­‐1.80 -­‐0.05 
2.54 1.01 5.14 0.17 
1 3 1 225 
0.42 1.55 -­‐0.35 -­‐0.28 
0.749 0.220 0.786 0.780 
Note: Weight is in kg. Fasting Glucose, Total cholesterol, and Triglycerides are in mg/dL. MET 
is an abbreviation for metformin. B.L. is an abbreviation for baseline. Time*MET is an 
abbreviation for time-by-metformin (time-by-treatment). 
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Table 5 
Solution for Fixed Effects for Metabolic Variables: Quetiapine 
Effect Variable Estimate St. Error DF t-Value Pr>|t| 
B.L. (𝛽!) 
 
Cholesterol 
Glucose 
Triglycerides 
Weight 
237.43	  .	  126.17	  93.48 
24.21	  .	  48.01	  6.57 
15	  .	  15	  15 
9.81	  .	  2.63	  14.23 
<0.001	  .	  0.019	  <0.001 
MET (𝛽!) Cholesterol 
Glucose 
Triglycerides 
Weight 
-­‐51.09	  .	  22.32	  4.75 
29.75 
. 58.67 8.17 
4 
. 4 126 
-­‐1.72 
. 0.38 0.58 
0.161 
. 0.723 0.562 
Time (𝛽!) Cholesterol 
Glucose 
Triglycerides 
Weight 
-­‐5.58 
. 3.70 -­‐0.07 
2.67 
. 5.16 0.21 
15 
. 15 15 
-­‐2.09 
. 0.72 -­‐0.35 
0.054 
. 0.484 0.731 
Time*MET 
(𝛽!) Cholesterol Glucose 
Triglycerides 
Weight 
5.44 
. -­‐6.06 -­‐0.06 
3.33 
. 6.42 0.26 
4 
. 4 126 
1.63 
. -­‐0.94 -­‐0.23 
0.178 
. 0.399 0.822 
Note: Weight is in kg. Fasting Glucose, Total cholesterol, and Triglycerides are in mg/dL. MET 
is an abbreviation for metformin. B.L. is an abbreviation for baseline. Time*MET is an 
abbreviation for time-by-metformin (time-by-treatment). 
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Table 6 
Metabolic Responses and Comparisons across Individual Antipsychotic Groups 
Antipsychotic Variable Placebo Group Metformin Group Between-Group 
Difference 
  Baseline Final ∆!"#  Baseline Final ∆!"#  ∆!"# − ∆!"# 
Aripiprazole 
 
 
 
 
 
 
 
Clozapine 
 
 
 
 
 
 
 
 
Olanzapine 
 
 
 
 
 
 
 
 
Risperidone 
 
 
 
 
 
 
 
 
Quetiapine 
Cholesterol 
Glucose 
TRI 
Weight	  
 
Cholesterol 
Glucose 
TRI 
Weight	  
 
Cholesterol 
Glucose 
TRI 
Weight	  
 
Cholesterol 
Glucose 
TRI 
Weight	  
 
Cholesterol 
Glucose 
TRI 
Weight	  
     184.1      172.4     -11.7     
                               -6.3% 
     87.8      106.3        18.5    
                                21.0% 
     159.8      263.7     103.9     
                                65.0% 
     92.1       91.0          -1.1 
                                -1.2% 
 
     206.5      180.1     -26.4     
                               -12.8% 
     108.5      102.7       -5.8     
                                -5.3% 
     229.1      179.4     -49.6   
                               -21.7% 
     103.3      102.2       -1.1     
                                 -1.1% 
 
     196.1      199.7        3.6     
                                 1.8% 
     96.8        85.9      -10.9     
                               -11.3% 
     207.6      65.6     -142.0   
                               -68.4% 
     104.6      102.9      -1.7     
                                -1.6% 
 
     211.9      219.7       7.8     
                                  3.7% 
     109.2       85.3      -23.9    
                                -21.9% 
     127.0     209.5       82.6    
                                65.0% 
     102.3      99.6        -2.7     
                                -2.6% 
 
     237.4      148.1     -89.3     
                               -37.6% 
        –	  	  	  	  	  	  	  	  	  	  	  –            –     
                                    – 
     126.2      185.4      59.3     
                                47.0% 
     93.5        92.3        -1.2    
                                -1.2% 
     175.4      214.7      39.2     
                                22.3% 
     96.2         89.5        -6.7     
                                 -7.0% 
     122.7      173.0       50.4     
                                 41.1% 
     100.5       96.2         -4.3 
                                 -4.3% 
 
     171.0      201.6       30.6 
                                 17.9% 
     100.7      94.0          -6.7    
                                 -6.6% 
     155.3      166.5       11.1     
                                   7.2% 
     105.0      96.6          -8.4     
                                 -8.0%	  
	  
     181.6      180.5       -1.1     
                                -0.6% 
     105.5      84.5       -20.9     
                               -19.8% 
     186.0      131.9     -54.1     
                               -29.1% 
     100.7      96.1        -4.5     
                                -4.5% 
 
     161.2      185.9      24.7    
                              15.3% 
     91.9        93.0          1.1   
                                   1.2% 
     102.5      156.3       53.8     
                                 52.5% 
     102.1      98.6         -3.4     
                                 -3.4% 
 
     186.3      184.0     -2.3     
                                -1.2% 
         –	  	  	  	  	  	  	  	  	  	  	  –           –     
                                    – 
     148.5      110.9     -37.6     
                               -25.3% 
     98.2         96.1       -2.1     
                                -2.1% 
50.9 
28.6% 
-25.2 
-28.0% 
-53.5 
-23.9% 
-3.2 
-3.1% 
 
57.0 
30.7% 
-0.9 
-1.3% 
60.8 
28.9% 
-7.3 
-6.9% 
 
-4.8 
-2.4% 
-10.0 
-8.5% 
88.0 
39.3% 
-2.8 
-2.9% 
 
16.9 
11.6% 
25.0 
20.7% 
-28.8 
-12.5% 
-0.7 
-0.8% 
 
87.0 
36.4% – – 
          -96.9 
-72.3% 
-0.9 
-0.9% 
Note: TRI is an abbreviation of triglycerides. Weight is in kg. Fasting Glucose, Total 
cholesterol, and Triglycerides are all in mg/dL. 
 
ANTIPSYCHOTIC-SPECIFIC ANALYSIS OF METS 
	  
28 
 
Figure 1: Weight change across conditions 
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Figure 2: Total cholesterol change across conditions 
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Figure 3: Fasting glucose change across conditions 
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Figure 4: Triglycerides change across conditions 
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